ASCO 2023 | PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study

Jeremie Calais, MD, MSc, University of California, Los Angeles, CA, discusses a retrospective study on PSMA PET tumor–to–salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy. A total of 237 men were included, and PSG scores were calculated based on quantitative and visual assessments of baseline PSMA PET images. Patients were categorized into high, intermediate, and low PSG score groups. The study found that a higher PSG score was associated with a greater decline in prostate-specific antigen (PSA) levels, longer PSA progression-free survival, and improved overall survival. Both the quantitative and visual PSG scores demonstrated substantial reproducibility and comparable prognostic value. The PSG score can serve as a prognostic tool for predicting treatment response and outcomes in mCRPC patients receiving PSMA-targeted radioligand therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.